Abstract

There was an excess of deaths due to arrhythmia and deaths due to shock after acute recurrent myocardial infarction in patients treated with encainide or flecainide. Nonlethal events, however, were equally distributed between the active-drug and placebo groups. The mechanisms underlying the excess mortality during treatment with encainide or flecainide remain unknown.

Keywords

FlecainideMedicinePlaceboInternal medicineCardiologyRandomizationMyocardial infarctionAnesthesiaIncidence (geometry)PharmacokineticsRandomized controlled trialAtrial fibrillation

Affiliated Institutions

Related Publications

Publication Info

Year
1991
Type
article
Volume
324
Issue
12
Pages
781-788
Citations
3193
Access
Closed

External Links

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

3193
OpenAlex

Cite This

Debra S. Echt, Philip R. Liebson, L. Brent Mitchell et al. (1991). Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or Placebo. New England Journal of Medicine , 324 (12) , 781-788. https://doi.org/10.1056/nejm199103213241201

Identifiers

DOI
10.1056/nejm199103213241201